Key facts
- THE PHAGE’s last known valuation is $10.5M (Sep 2024).
- It has raised $3.1M; the latest was Early Stage VC in Feb 2026.
- Notable investors include Plug and Play Tech Center, Mizuho Capital, Genesia Ventures, Intellectual Property Acceleration Program for Startups, 0>1 Start — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for THE PHAGE
- ·The full record, as it builds
Funding rounds
No funding rounds for THE PHAGE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About THE PHAGE
Developer of a diabetes treatment application designed to analyze biometric data and daily activities to provide personalized health insights. The company's application leverages artificial intelligence to automatically predict blood glucose levels for type 2 diabetes patients, enabling individuals to make informed lifestyle changes and take control of their health.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2021
- Employees
- 23
- Website
- thephage.life/
- Ownership
- Privately Held (backing)
THE PHAGE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in THE PHAGE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on THE PHAGE in its N-PORT filings yet. We sweep new filings monthly.